
Access to life-extending HIV and AIDS drugs in developing countries has improved during the past three years, but new infections still dramatically outpace efforts to bring treatment to patients, health officials said Monday.
Three years ago, fewer than 300,000 people in the developing world were receiving the antiretroviral drugs that help treat the virus. Last year, 2.2 million people in developing countries received the drugs, according to Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases.
''However, for every one person that you put in therapy, six new people get infected. So we're losing that game, the numbers game,'' Fauci told Australian Broadcasting Corp. radio.
In many parts of the developing world where the AIDS epidemic is still growing exponentially, effective prevention strategies—such as condom distribution, needle exchanges, and basic education about the disease—reach less than 15% of the population.
''The proven prevention modalities are not accessible to any substantial proportion of the people who need them,'' said Fauci, one of the keynote speakers at the Fourth International AIDS Society Conference on HIV Pathogenesis and Treatment in Sydney, Australia, which runs through Wednesday.
''Although we are making major improvements in the access to drugs, clearly prevention must be addressed in a very forceful way,'' he added.
According to recent World Health Organization statistics, only 28% of the world's HIV and AIDS patients are receiving antiretroviral drugs.
Dr. Brian Gazzard, chairman of the British HIV Association, said that while great advances have been made in extending access to antiretrovirals, the disease is still running rampant in parts of Asia and Africa.
''The HIV epidemic is essentially uncontrolled, uncontrolled in Africa, uncontrolled completely in Asia right now,'' he told reporters at the conference, which has drawn 5,000 delegates from 133 countries. ''The epidemic still is in an exponential growth phase ... and I think that is likely to continue.'' (AP)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.